Immuno-Oncology 360, NYC 2018

Immuno-Oncology 360° is a comprehensive program providing exposure to the entire spectrum of R and D, addressing aspects from all facets of IO including: Discovery/Preclinical Science Translational Science Clinical Development Business Aspects Investor Relations Emerging Technologies Biomarkers / Diagnostics Trends in the Field Lead Advisors Dr Axel Hoos, GSK, and Dr James Gulley, NCI, developed the 4th annual IO360° program to include 45 speakers and over 30 talks. Dr Andrew Baum is the investor relations plenary keynote. IO360° provides the most up-to-date research, data and progress to help IO stakeholders: Be at the forefront of relevant research and developments from key leadership who are at the pulse of cancer immunotherapy Foster collaboration amongst those working in all aspects of cancer immunotherapy together under one roof​ Receive the latest pre-clinical, translational and clinical data from academic and industry Gain a greater understanding of what assets are available for potential combinations Create and prioritize strategies targeted toward specific tumor types​ Hear from IO clinical trial leaders as they cover trial design, clinical operations, the latest outcomes and lessons learned Get key investor and analyst evaluations and insights on the IO landscape, challenges and what’s next Hear reports on industry trends from Endpoint News and BioCentury Innovations and a progress update on the Cancer Moonshot Learn about biomarker advancements in vaccines, imaging, neoantigen approaches and more Obtain coverage on a wide range of emerging technologies Pharma and Biotech Special Rate: To support IO teams in drug development, the registration fee for pharma and biotech companies includes a guest pass for a colleague from within the same company who has not yet attended IO360°. Guest pass must be claimed by Nov. 3, 2017. Email [email protected] for sponsorship and exhibitor opportunities.